Security Snapshot

Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 per share (KTTA) Institutional Ownership

CUSIP: 70261F202

13F Institutional Holders and Ownership History from Q1 2024 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

24

Shares (Excl. Options)

12,892,082

Price

$1.29

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
KTTA on Nasdaq
Shares outstanding
24,934,935
Price per share
$0.84
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
12,892,082
Total reported value
$16,641,289
% of total 13F portfolios
0%
Share change
+10,180,078
Value change
+$13,193,231
Number of holders
24
Price from insider filings
$0.84
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 per share is tracked under CUSIP 70261F202.
  • 24 institutions reported positions in Q4 2025.
  • 12 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 18 to 24 between Q3 2025 and Q4 2025.
  • Reported value moved from $441,403 to $16,641,289.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Official SEC Source

Backed by Form 13F

Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.

See Original Filing

Investment Quick Answers

What is CUSIP 70261F202?
CUSIP 70261F202 identifies KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 per share (KTTA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Vivo Opportunity Fund Holdings, L.P. 10% $12,292,327 17,560,467 Vivo Opportunity Fund Holdings, L.P. 01 Dec 2025
JANUS HENDERSON GROUP PLC 10% $7,160,756 10,229,652 JANUS HENDERSON GROUP PLC 28 Nov 2025
Opaleye Management Inc. 10% $2,092,440 2,491,000 Opaleye Management Inc. 01 Apr 2026
Coastlands Capital LP 10% $2,059,498 2,394,765 Coastlands Capital LP 23 Feb 2026
Squadron Capital Management LLC 9.9% 0% $2,050,179 +$67,601 2,329,749 +3.4% Squadron Master Fund LP 31 Dec 2025
Adage Capital Management, L.P. 10% $2,050,179 2,329,749 Adage Capital Management, L.P. 31 Dec 2025
AMERIPRISE FINANCIAL INC 8.4% $1,698,513 1,930,128 Ameriprise Financial, Inc. 31 Dec 2025
CVI Investments, Inc. 3.8% -61% $791,995 +$64,987 899,994 +8.9% CVI Investments, Inc. 31 Dec 2025
Orca Capital AG 4.9% -13% $613,228 -$14,002 362,857 -2.2% Orca Capital AG 07 May 2025
INTRACOASTAL CAPITAL, LLC 5% $537,188 317,863 Mitchell P. Kopin 06 May 2025
ARMISTICE CAPITAL, LLC 5% -50% $240,119 +$14,019 142,082 +6.2% Armistice Capital, LLC 31 Mar 2025
STEINMAN LAWRENCE 3.1% $141,720 83,858 Lawrence Steinman 01 Mar 2025

As of 31 Dec 2025, 24 institutional investors reported holding 12,892,082 shares of Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 per share (KTTA). This represents 52% of the company’s total 24,934,935 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 per share (KTTA) together control 52% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Squadron Capital Management LLC 8.4% 2,100,000 0% 1.2% $2,709,000
JANUS HENDERSON GROUP PLC 8.4% 2,100,000 0% $2,719,500
Vivo Capital, LLC 8.4% 2,100,000 0.18% $2,709,000
ADAGE CAPITAL PARTNERS GP, L.L.C. 8.4% 2,100,000 0% $2,709,000
AMERIPRISE FINANCIAL INC 7.7% 1,930,128 0% $2,489,865
Cable Car Capital, LP 2% 500,000 0.04% $645,000
ACUTA CAPITAL PARTNERS, LLC 1.8% 450,000 0.39% $580,500
STEMPOINT CAPITAL LP 1.4% 355,082 0.08% $458,056
AdvisorShares Investments LLC 1.2% 304,721 +18% 0.07% $393,090
Persistent Asset Partners Ltd 1.2% 290,555 0.18% $374,816
Stonepine Capital Management, LLC 1.1% 275,062 0.28% $354,830
VANGUARD GROUP INC 0.39% 97,675 +82% 0% $126,000
JANE STREET GROUP, LLC 0.24% 59,372 +137% 0% $76,590
CITADEL ADVISORS LLC 0.23% 56,183 -17% 0% $72,476
GEODE CAPITAL MANAGEMENT, LLC 0.22% 54,495 +114% 0% $70,302
TWO SIGMA INVESTMENTS, LP 0.2% 48,773 +36% 0% $62,917
NORTHERN TRUST CORP 0.11% 28,090 0% $36,236
XTX Topco Ltd 0.08% 20,783 -40% 0% $26,810
UBS Group AG 0.05% 13,263 -28% 0% $17,109
Hurley Capital, LLC 0.01% 3,689 0% 0% $4,759
Tower Research Capital LLC (TRC) 0.01% 2,947 +142% 0% $3,802
SBI Securities Co., Ltd. 0% 1,051 0% 0% $1,356
JPMORGAN CHASE & CO 0% 150 0% 0% $194
BANK OF AMERICA CORP /DE/ 0% 63 +8.6% 0% $81
Virtu Financial LLC 0% 0 -100% $0

Institutional Holders of Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 per share (KTTA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 12,892,082 $16,641,289 +$13,193,231 $1.29 24
2025 Q3 612,004 $441,403 +$224,539 $0.73 18
2025 Q2 300,344 $216,624 +$151,923 $0.72 10
2025 Q1 78,704 $99,102 -$116,583 $1.30 7
2024 Q4 77,162 $243,273 +$214,440 $3.15 7
2024 Q3 9,086 $48,891 -$103,371 $5.42 6
2024 Q2 29,996 $151,569 -$300 $5.06 7
2024 Q1 30,055 $218,102 +$218,102 $7.28 6

Sponsored